Horizon Pharma shares offer 'significant value,' says Stifel Stifel sees "significant value" in shares of Horizon Pharma with today's pullback and it keeps a Buy rating on the name. The firm says Express Scripts and Caremark putting Duexis and Vimovo on their exclusion lists is a "large disappointment," but it believes management has several avenues to offset the impact. Stifel lowered its price target for shares to $20 from $25.
Hyperion Therapeutics downgraded to Hold from Buy at Brean Capital Brean Capital downgraded Hyperion Therapeutics (HPTX) citing the takeover by Horizon Pharma (HZNP). Brean views the buyout price as "reasonable and fair."